Small molecules that drug traditionally undruggable targets
3 additional undisclosed programs RD oncology
BridGene Biosciences is developing small molecules intended to target previously undruggable targets. Currently, about 90% of disease-associated diseases cannot be targeted by traditional therapies as addressable binding sites are unknown. BridGene is using their chemoproteomics platform, IMTACTM, to screen small molecules against all proteins in live cells to discover drug candidates for high value and hard-to-drug targets. The IMTACTM platform uses covalent chemistry, chemical proteomics and quantitative mass spectrometry to screen cells in different cellular states and different cell compartments to greatly increase the application scope of BridGene’s chemoproteomic technology. Using their platform, BridGene is advancing a deep and diversified pipeline focusing on new oncology drugs.